Decreased Serum Hepatocyte Growth Factor (HGF) in Autistic Children with severe Gastrointestinal Disease

Biomarker Insights

Volumn 4, Issue , 2009, Pages

  Russo, A J ^a   Krigsman, A ^b   Jepson, B ^b   Wakefield, Andrew ^b  

^a Pfeiffer Treatment Center   (United States)

^b Thoughtful House Center for Children   (United States)

Author keywords

autism; GI disease; hepatocyte growth factor; met gene

Indexed keywords

EID: 85128452824     PISSN: None     EISSN: 11772719     Source Type: Journal    
DOI: 10.4137/BMI.S3656     Document Type: Article

References (64)

1. Muhle R., Trentacoste S.V., Rapin I. The Genetics of Autism. Pediatrics. 2004; 113: e472–86.
2. Yeargin-Allsopp M., Rice C., Karapurkar T., Doernberg N., Boyle C., Murphy C. Prevalence of Autism in a US Metropolitan Area. J Am Med Assoc. 2003; 289: 49–55.
3. Le Couteur A., Bailey A., Goode S. et al. A broader phenotype of autism: the clinical spectrum in twins. J Child Psychol Psychiatry. 1996; 37: 785–801.
4. Fombonne E. Epidemiological surveys of autism and other pervasive developmental disorders: an update. J Autism Dev Disord. 2003; 33: 365–82.
5. Barrett S., Beck J.C., Bernier R. et al. An autosomal genomic screen for autism. Collaborative linkage study of autism. Am J Med Genet. 1999; 88: 609–15.
6. International Molecular Genetics Study of Autism Consortium Further characterization of the autism susceptibility locus AUTS1 on chromosome 7q. Hum Mol Genet. 2001; 10: 973–82.
7. Yonan A.L., Alarcon M., Cheng R. et al. A genomewide screen of 345 families for autism-susceptibility loci. Am J Hum Genet. 2003; 73: 886–97.
8. Hutcheson H.B., Olson L.M., Bradford Y. et al. Examination of NRCAM, LRRN3, KIAA0716, and LAMB1 as autism candidate genes. BMC Med Genet. 2004; 5: 12.
9. Valicenti-McDermott M., McVicar K., Rapin I., Wershil B.K., Cohen H., Shinnar S. Frequency of gastrointestinal symptoms in children with autistic spectrum disorders and association with family history of autoimmune disease. J Dev Behav Pediatr. 2006; 27: S128–36.
10. Jyonouchi H., Geng L., Ruby A., Zimmerman-Bier B. Dysregulated innate immune responses in young children with autism spectrum disorders: their relationship to gastrointestinal symptoms and dietary intervention. Neuropsychobiology. 2005; 51: 77–85.
11. White J.F. Intestinal Pathophysiology in Autism. Exp Biol Med (Maywood). 2003; 228: 639–49.
12. Russo A.J., Krigsman A., Jepson B., Wakefield A. Low serum Alpha-1 Antitrypsin Associated with Anti-PR3 ANCA in Autistic children with GI disease. Genomics Insights. 2009; 2: 1–9.
13. Russo A.J., Krigsman A., Jepson B., Wakefield A. Anti-PR3 and Anti-MPO IgG ANCA in Autistic Children With Chronic GI disease. Immunology and Immunogenetics Insights. 2009; 2: 21–8.
14. Russo A.J. Anti-Metallothionein IgG and levels of metallothionein in autistic families. Swiss Med Weekly. 2008; 138(5-6): 70–7.
15. Russo A.J. Anti-metallothionein IgG and levels of metallothionein in autistic children with GI disease. Drug Healthcare and Patient Safety. 2009; 1: 1–8.
16. Campbell D. et al. A genetic variant that disrupts MET transcription is associated with autism. PNAS. 2006; 103: 16834–9.
17. Huh C.G., Factor V.M., Sanchez A., Uchida K., Conner E.A., Thorgeirsson S.S. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci USA. 2004; 101: 4477–82.
18. Tahara Y., Ido A., Yamamoto S. et al. Hepatocyte Growth Factor Facilitates Colonic Mucosal Repair in Experimental Ulcerative Colitis in Rats. J Pharmacol Exp Ther. 2003; 307: 146–51.
19. Zhang Y.W., Vande Woude G.F. HGF/SF-met signaling in the control of branching morphogenesis and invasion. J Cell Biochem. 2003; 88: 408–17.
20. Okunishi K., Dohi M., Nakagome K. et al. A Novel Role of Hepatocyte Growth Factor as an Immune Regulator through Suppressing Dendritic Cell Function. J Immunol. 2005; 175: 4745–53.
21. Beilmann M., Odenthal M., Jung W., Vande Woude G.F., Dienes H.P., Schirmacher P. Neoexpression ofthe c-met/Hepatocyte Growth Factor-Scatter Factor Receptor Gene in Activated Monocytes. Blood. 1997; 90: 4450–8.
22. Beilmann M., Vande Woude G.F., Dienes H.P., Schirmacher P. Hepatocyte growth factor-stimulated invasiveness of monocytes. Blood. 2000; 95: 3964–9.
23. Arthur L.G., Schwartz M.Z., Kuenzler K.A., Birbe R. Hepatocyte growth factor treatment ameliorates diarrhea and bowel inflammation in a rat model of inflammatory bowel disease. J Pediatr Surg. 2004; 39: 139–43, discussion 139–43.
24. Ido A., Numata M., Kodama M., Tsubouchi H. Mucosal repair and growth factors: recombinant human hepatocyte growth factor as an innovative therapy for inflammatory bowel disease. J Gastroenterol. 2005; 40: 925–31.
25. Ieraci A., Forni P.E., Ponzetto C. Viable hypomorphic signaling mutant of the Met receptor reveals a role for hepatocyte growth factor in postnatal cerebellar development. Proc Natl Acad Sci USA. 2002; 99: 15200–5.
26. Palmen S.J., van Engeland H., Hof P.R., Schmitz C. Neuropathological findings in autism. Brain. 2004; 127: 2572–83.
27. Courchesne E., Redcay E., Kennedy D.P. The autistic brain: birth through adulthood. Curr Opin Neurol. 2004; 17: 489–96.
28. Powell E.M., Mars W.M., Levitt P. Hepatocyte growth factor/scatter factor is a motogen for interneurons migrating from the ventral to dorsal telencephalon. Neuron. 2001; 30: 7989.
29. Powell E.M., Campbell D.B., Stanwood G.D., Davis C., Noebels J.L., Levitt P. Genetic Disruption of Cortical Interneuron Development Causes Region- and GABA Cell Type-Specific Deficits, Epilepsy, and Behavioral Dysfunction. J Neurosci. 2003; 23: 622–31.
30. Tuchman R., Rapin I. Epilepsy in autism. Lancet Neurol. 2002; 1: 352–8.
31. Levitt P., Eagleson K.L., Powell E.M. Regulation of neocortical interneuron development and the implications for neurodevelopmental disorders. Trends Neurosci. 2004; 27: 400–6.
32. Nakamura T. et al. Purification and characterization of a growth factor from rat platelets for mature parenchymal hepatocytes in primary cultures. Proc Natl Acad Sci USA. 1986; 83: 6489.
33. Nakamura T. et al. Partial Purification and Characterization in hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun. 1984; 122: 1450.
34. Sasaki M. et al. Identification of mouse mammary fibroblast-derived mammary growth factor as hepatocyte growth factor. Biochem Biophys Res Commun. 1994; 199: 772.
35. Michalopoulos G. et al. Control of Hepatocyte Replication by Two Serum Factors. Cancer Res. 1984; 44: 4414.
36. Thaler F.J., Michalopoulos G. Hepatopoietin A: Partial Characterization and Trypsin Activation of a Hepatocyte Growth Factor. Cancer Res. 1985; 45: 2545.
37. Zarnegar R., Michalopoulos G.K. The many faces of hepatocyte growth factor: from hepatopoiesis to hematopoiesis. J Cell Biol. 1995; 129: 1177.
38. Weidner K.M. et al. Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proc Natl Acad Sci USA. 1991; 88: 7001–5.
39. Comoglio P.M., Graziani A. In Guidebook to Cytokines and their Receptors, Nicola N.A., ed., Oxford University Press, 1994: 182.
40. Comoglio P.M., Graziani A. In Guidebook to Cytokines and their Receptors, Nicola N.A. ed., Oxford University Press, 1994: 185.
41. Grant D.S. et al. Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci USA. 1993; 90: 1937–41.
42. Birchmeier C., Birchmeier W., Gherardi E., Vande Woude G.F. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003; 4: 915–25.
43. Yo Y.R., Morishita K., Yamamoto N. et al. Ogihara, Actions of hepatocyte growth factor as a local modulator in the kidney: potential role in pathogenesis of renal disease. Kidney Int. 1998; 53: 50–8.
44. Elliott B.E., Hung W.L., Boag A.H., Tuck A.B. The role of hepatocyte growth factor (scatter factor) in epithelial-mesenchymal transition and breast cancer. Can J Physiol Pharmacol. 2002; 80: 91–102.
45. Sugihara G., Hashimoto K., Iwata Y. et al. Decreased serum levels of hepatocyte growth factor in male adults with high-functioning autism. Prog Neuropsychoph Biol Psychiatry. 2007; 31: 412–5.
46. Li Z., Mizuno S., Nakamura T. Antinecrotic and antiapoptotic effects of hepatocyte growth factor on cholestatic hepatitis in a mouse model of bile-obstructive diseases. Am J Physiol Gastrointest Liver Physiol. 2007; 292: G639–46.
47. Ekuni D., Firth J.D., Putnins E.E. Regulation of epithelial cell growth factor receptor protein and gene expression using a rat periodontitis model. J Periodontal Res. 2006; 41: 340–9.
48. Kurz S.M., Diebold S.S., Hieronymus T. et al. The impact of c-met/scatter factor receptor on dendritic cell migration. Eur J Immunol. 2002; 32: 1832–8.
49. Horvath K., Perman J. Autistic disorder and gastrointestinal disease. Curr Opin Pediat. 2002; 14: (5): 583–7.
50. Molloy C., Manning-Courtney P. Prevalence of chronic gastrointestinal symptoms in children with autism and autistic spectrum disorders. Autism. 2003; 7: (2): 165–71.
51. Valicenti-McDermott M., McVicar K., Rapin I. Frequency of gastrointestinal symptoms in children with autistic spectrum disorders and association with family history of autoimmune disease. J Dev Behav Pediatr. 2006; 27: (Suppl 2): S128–36.
52. Ashwood P. et al. Intestinal lymphocyte populations in children with regressive autism: evidence for extensive mucosal immunopathology. J Clin Immunol Nov. 2003; 23(6): 504–17.
53. Balzola F. et al. Autistic enterocolitis: confirmation of a new inflammatory bowel disease in an Italian cohort of patients. Gastroenterology. 2005; 128: Suppl 2: A-303.
54. Wakefield A.J. et al. Review article: the concept of entero-colonic encephalopathy, autism and opioid receptor ligands. Aliment Pharmacol Ther. 2002; 16(4): 663–74.
55. Wakefield A.J. et al. Enterocolitis in children with developmental disorders. Am J Gastroenterol. 2000 Sep; 95(9): 2285–95.
56. Russo A.J., Krigsman A., Jepson B., Wakefield A. Anti-PR3 and Anti-MPO IgG ANCA in Autistic Children with Chronic GI Disease. Immunology and Immunogenetics Insights. 2009; 2: 21–8.
57. Russo A.J., Krigsman A., Jepson B., Wakefield A. Low Serum Alpha-1 Antitrypsin Associated with Anti-PR-3 ANCA in Autistic Children with GI Disease Genomics Insights. 2009; 2: 1–9.
58. Schanen C.N. Epigenetics of autism spectrum disorders. Human Molecular Genetics. 2006; 15: 138–50.
59. Campbell. Distinct genetic risk based on association of MET in families with co-occurring autism and gastrointestinal conditions. Pediatrics. 2009; 123(3): 1018–24.
60. Levitt P., Campbell D.B. The genetic and neurobiologic compass points toward common signaling dysfunctions in autism spectrum disorders. J Clin Invest. 2009; 119(4): 747–54.
61. McCall-Culbreath K.D., Li Z., Zutter M.M. Crosstalk between the alpha2beta1 integrin and c-met/HGF-Rregulatesinnateimmunity. Blood. 2008; 111(7): 3562–70.
62. Sousa I., Clark T.G., Toma C., Kobayashi K., Choma M., Holt R. et al. MET and autism susceptibility: family and case-control studies. Eur J Hum Genet. 2009; 17(6): 749–58.
63. Okada et al. Decreased serum levels of transforming growth factor-β1 in patients with autism Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2007; 31: 187–90.
64. Suzuki et al. Decreased Serum Levels of Epidermal Growth Factor in Adult Subjects with High-Functioning Autism Biological Psychiatry. 2007; 62: 267–9.